IMUNON (IMNN) announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of IMNN-001 to treat women with newly diagnosed advanced ovarian cancer was accepted for oral presentation at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. The meeting is being held May 30 – June 3, 2025, in Chicago, Illinois and virtually. IMUNON recently announced alignment with the U.S. Food and Drug Administration, FDA, on the study protocol for the Phase 3 OVATION 3 clinical trial of IMNN-001 and has initiated trial site activation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- Imunon files to sell 10M shares of common stock, warrants
- Imunon Receives Buy Rating for Strategic Focus and Cost-Effective OVATION 3 Trial
- Imunon finalizes Phase 3 study design with FDA for IMNN-001
- Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating
- IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs